{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:12:03Z","timestamp":1778739123396,"version":"3.51.4"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Antiangiogenic therapy and immune checkpoint inhibitors represent two cornerstone approaches in the current systemic treatment of patients with hepatocellular carcinoma (HCC). Since the advent of the immunotherapy era, the survival of patients with HCC, particularly those with unresectable disease, has improved significantly. However, both drug classes carry the potential for vascular injury, with hypertension being a notable adverse event. Antiangiogenic agents, such as lenvatinib and bevacizumab, frequently induce hypertension. Given that the main systemic regimens for HCC often combine multiple agents prone to cause hypertension, effective management of blood pressure is crucial for long-term adherence to cancer treatment and survival. However, patients with HCC often present with underlying conditions such as cirrhosis, portal hypertension, and ascites. These conditions themselves or their treatments, such as diuretics and non-selective beta-blockers, may lower blood pressure, which is often accompanied by hypoperfusion of vital abdominal organs, particularly the kidneys, posing greater harm than hypertension alone. Consequently, blood pressure management in patients undergoing systemic HCC therapy is highly complex, necessitating the involvement of a ultidisciplinary team collaboration in future practice.<\/jats:p>","DOI":"10.3389\/fphar.2026.1780200","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:35:12Z","timestamp":1778736912000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypertension associated with systemic therapy for hepatocellular carcinoma and management strategies"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuqing","family":"Li","sequence":"first","affiliation":[{"name":"The People\u2019s Hospital of Qionghai City","place":["Qionghai, China"]},{"name":"China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boxuan","family":"Wang","sequence":"additional","affiliation":[{"name":"China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Hospital of Jilin University","place":["Changchun, China"]},{"name":"Huancheng Township Health Center Hospital","place":["Yushu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Xin","sequence":"additional","affiliation":[{"name":"Shenyang Institute of Engineering","place":["Shenyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingyu","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e70058","DOI":"10.1002\/edm2.70058","article-title":"Efficacy and safety of low-dose spironolactone in management of diabetic kidney disease in a real-world setting","volume":"8","author":"Amini","year":"2025","journal-title":"Endocrinol. Diabetes Metab."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3748\/wjg.v25.i20.2524","article-title":"Systematic review: renin-Angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma","volume":"25","author":"Barone","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/17425255.2018.1461839","article-title":"Lenvatinib-induced renal failure: two first-time case reports and review of literature","volume":"14","author":"Cavalieri","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S0140-6736(25)01042-6","article-title":"The lancet commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment","volume":"406","author":"Chan","year":"2025","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.7150\/ijms.103390","article-title":"Low-dose spironolactone combined with ACEIs\/ARBs may reduce cardiovascular events in patients with CKD stages 3b-5: a nationwide population-based cohort study in Taiwan","volume":"22","author":"Chien","year":"2025","journal-title":"Int. J. Med. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00395-024-01046-0","article-title":"Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin","volume":"120","author":"Efentakis","year":"2024","journal-title":"Basic Res. Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12882-018-1074-3","article-title":"Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report","volume":"19","author":"Furuto","year":"2018","journal-title":"BMC Nephrol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1001\/jamaoncol.2025.4543","article-title":"Immune checkpoint inhibitor\u2013associated cardiovascular toxic effects","volume":"12","author":"Herrmann","year":"2026","journal-title":"JAMA Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1002\/cam4.2241","article-title":"Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis","volume":"8","author":"Hiraoka","year":"2019","journal-title":"Cancer Med."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-025-09453-6","article-title":"Comparative risk of recurrent esophageal variceal hemorrhage and other decompensation events with carvedilol versus propranolol in patients with cirrhosis: a retrospective study","author":"Ismail","year":"2025","journal-title":"Dig. Dis. Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"100316","DOI":"10.1016\/j.jhepr.2021.100316","article-title":"Portal hypertension in cirrhosis: pathophysiological mechanisms and therapy","volume":"3","author":"Iwakiri","year":"2021","journal-title":"JHEP Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"913464","DOI":"10.3389\/fimmu.2022.913464","article-title":"The significance of transarterial Chemo(Embolization) combined with tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma in the era of systemic therapy: a systematic review","volume":"13","author":"Ke","year":"2022","journal-title":"Front. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1038\/s41440-025-02197-w","article-title":"Is lenvatinib-induced blood pressure elevation a favorable prognostic factor in patients with hepatocellular carcinoma?","volume":"48","author":"Kidoguchi","year":"2025","journal-title":"Hypertens. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1053\/j.akdh.2023.07.002","article-title":"Hepato-cardio-renal syndrome","volume":"31","author":"Koratala","year":"2024","journal-title":"Adv. Kidney Dis. Health"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"104462","DOI":"10.1016\/j.jpain.2024.01.005","article-title":"Endothelial glycocalyx in the peripheral capillaries is injured under oxaliplatin-induced neuropathy","volume":"25","author":"Kuroda","year":"2024","journal-title":"J. Pain"},{"key":"B22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1200\/JCO.21.00608","article-title":"Hepatic arterial infusion of Oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2147\/DDDT.S443107","article-title":"Understanding Sorafenib-Induced cardiovascular toxicity: mechanisms and treatment implications","volume":"18","author":"Li","year":"2024","journal-title":"Drug Des. Devel Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/08037051.2021.1880881","article-title":"A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes","volume":"30","author":"Lin","year":"2021","journal-title":"Blood Press"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1010726","DOI":"10.3389\/fonc.2022.1010726","article-title":"Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: a meta-analysis","volume":"12","author":"Luo","year":"2022","journal-title":"Front. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s44222-023-00144-3","article-title":"Modelling and targeting mechanical forces in organ fibrosis","volume":"2","author":"Mascharak","year":"2024","journal-title":"Nat. Rev. Bioeng."},{"key":"B27","doi-asserted-by":"publisher","first-page":"5807","DOI":"10.3390\/ijms25115807","article-title":"The renin-angiotensin System in liver disease","volume":"25","author":"McGrath","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1161\/HYPERTENSIONAHA.122.19865","article-title":"Immune checkpoint inhibitors do not increase short-term risk of hypertension in cancer patients: a systematic literature review and meta-analysis","volume":"79","author":"Minegishi","year":"2022","journal-title":"Hypertension"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1210\/clinem\/dgad144","article-title":"Efficacy and safety of low-dose spironolactone for chronic kidney disease in type 2 diabetes","volume":"108","author":"Oiwa","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B30","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jaccao.2020.08.007","article-title":"Immune checkpoint inhibitor therapy aggravates T cell\u2013driven plaque inflammation in atherosclerosis","volume":"2","author":"Poels","year":"2020","journal-title":"JACC CardioOncology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1200\/JCO.2012.44.5643","article-title":"Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil\/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia","volume":"31","author":"Qin","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S2468-1253(21)00109-6","article-title":"Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"6","author":"Qin","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"gfz103.SP056","DOI":"10.1093\/ndt\/gfz103.sp056","article-title":"SP056Influence of lenvatinib on blood pressure and its related clinical factors","volume":"34","author":"Saito","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"B37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/ckj\/sfaa137","article-title":"Changes in blood pressure during treatment with the tyrosine kinase inhibitor lenvatinib","volume":"14","author":"Saito","year":"2020","journal-title":"Clin. Kidney J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/annonc\/mdn637","article-title":"Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab","volume":"20","author":"Scartozzi","year":"2009","journal-title":"Ann. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S2468-1253(25)00059-7","article-title":"Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial","volume":"10","author":"Shi","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/s41440-025-02149-4","article-title":"Blood pressure elevations post-lenvatinib treatment in hepatocellular carcinoma: a potential marker for better prognosis","volume":"48","author":"Shibata","year":"2025","journal-title":"Hypertens. Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"m2687","DOI":"10.1136\/bmj.m2687","article-title":"Hepatorenal syndrome: pathophysiology, diagnosis, and management","volume":"370","author":"Simonetto","year":"2020","journal-title":"BMJ"},{"key":"B42","first-page":"993","article-title":"Chinese expert consensus on integrated management of cancer-related hypertension (2024 version)","volume":"51","year":"2024","journal-title":"Chin. J. Clin. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/1750743X.2025.2504868","article-title":"New onset of hypertension associated with immune checkpoint inhibitor therapy in cancer patients","volume":"17","author":"Watson","year":"2025","journal-title":"Immunotherapy"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1002\/cncr.31344","article-title":"Treatment-emergent hypertension and efficacy in the phase 3 study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT)","volume":"124","author":"Wirth","year":"2018","journal-title":"Cancer"},{"key":"B46","article-title":"Cardio\u2010oncology expert committee of the chinese society of clinical oncology. Guidelines of chinese society of clinical oncology (CSCO): clinical practice guidelines for cardio\u2010oncology","author":"Xiaoyuan Chu","year":"2025"},{"key":"B47","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s12072-022-10480-y","article-title":"Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients","volume":"17","author":"Yang","year":"2023","journal-title":"Hepatol. Int."},{"key":"B48","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/hep.32294","article-title":"Angiotensin\u2010converting enzyme inhibitors prevent liver\u2010related events in nonalcoholic fatty liver disease","volume":"76","author":"Zhang","year":"2022","journal-title":"Hepatology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1159\/000546574","article-title":"China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 edition)","volume":"14","author":"Zhou","year":"2025","journal-title":"Liver Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1780200\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:35:21Z","timestamp":1778736921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1780200\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":49,"alternative-id":["10.3389\/fphar.2026.1780200"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1780200","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"article-number":"1780200"}}